One of Flagship’s startups appears to be buckling under the pressure of a steadily falling stock price. The microbiome company Kaleido Biosciences confirmed a new report that it’s laying off staff, but is holding back on details, with CEO Dan Menichella telling Endpoints News in a statement: We have taken steps to right-size the company … Continue reading Flagship startup brings out the budget ax, chops staff and clinical plans as share price flounders